INNOVATE Corp. Reports $1.246 Billion Revenue and Strategic Developments in 10-K Filing

INNOVATE Corp. Reports Financial Results and Strategic Developments in Form 10-K Filing

INNOVATE Corp., a diversified holding company, released its Form 10-K filing, detailing its financial performance and strategic activities. The filing reveals that INNOVATE's total revenue for the year ended December 31, 2025, reached $1.246 billion, an increase of $138.9 million compared to the $1.1071 billion reported for the previous year. This growth was primarily driven by the Infrastructure segment, with contributions from the Life Sciences segment, partially offset by a decrease in the Spectrum segment. The company reported a net loss attributable to INNOVATE Corp. of $60.6 million for 2025, compared to a net loss of $34.6 million in 2024.

The Infrastructure segment, represented by DBM Global Inc. (DBMG), saw its revenue increase by $138.7 million to $1.2103 billion. This was attributed to the timing and size of projects in DBMG's commercial structural steel fabrication and erection business. However, income from operations for the segment decreased by $10.3 million to $55.4 million, due to the effect of changes in estimated costs to complete those projects recognized in the ordinary course of business in the comparable year. The Life Sciences segment, which includes Pansend Life Sciences, LLC, experienced a revenue increase of $2.7 million, reaching $12.5 million, driven by R2 Technologies' Glacial Spa and Glacial fx unit sales outside North America. The Spectrum segment, however, saw a revenue decrease of $2.5 million, totaling $23.2 million, primarily due to the termination of certain customer contracts and a downturn in the direct response advertising market.

Strategic developments outlined in the filing include the commencement of sales processes for the Infrastructure and Spectrum segments, as required by milestone covenants in the company's debt agreements. Management has initiated these processes and is actively assessing potential options to optimize the company's operational and financial position. Following these potential sales, INNOVATE expects its strategic focus to shift towards operating and managing its remaining portfolio of companies and building value in its Life Sciences segment. The company also highlighted its ongoing evaluation of strategic and business alternatives within its operating segments, including potential acquisitions, business combinations, and debt or equity securities offerings.

Key operational developments and business indicators include DBMG's backlog of $1.7239 billion as of December 31, 2025, with approximately 66% attributable to five contracts. The filing also notes that DBMG operates with minimal bonding requirements, with 39.5% of its total backlog bonded. R2 Technologies, within the Life Sciences segment, utilizes a direct sales force in the United States and Canada and sells its products through distributors in international markets. Broadcasting, in the Spectrum segment, operated 257 stations as of December 31, 2025, reaching 112 markets in the U.S. and Puerto Rico. The company is also exploring commercial opportunities in datacasting on its platform, which may offer incremental revenue opportunities.

The filing also includes forward-looking statements regarding the company's future performance and strategic initiatives. INNOVATE acknowledges that its ability to generate cash depends on factors beyond its control and that failure to meet debt service obligations could harm its business, financial condition, and results of operations. The company also expresses substantial doubt about its ability to continue as a going concern within one year after the date that the financial statements are issued, due to the upcoming maturities of its debt obligations. INNOVATE plans to alleviate these conditions through various initiatives it is currently exploring, including pursuing asset sales, and potentially refinancing debt and raising additional capital.